Incorporating these factors into trial design and clinical practice may enable more individualized risk–benefit assessments, ensuring that GLP-1 RA are deployed not only for metabolic control but also as part of tailored strategies to mitigate diabetes-associated cancer risk. This evidence concerns the gene GLP1R and cancer.